N@N

MEDICINOVA INC (NASDAQ:MNOV), Up By 12.26% ($0.37) After BUYINS.NET SqueezeTrigger Report Released on Tuesday, May 1st 2012 at

^{Published on 2012-05-07 09:40:37 - WOPRAI}
 

May 7, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, released a report on Tuesday, May 1st 2012 at 07:15:00 PDT stating that MEDICINOVA INC (NASDAQ:MNOV) was expected to be Up After it crossed above its SqueezeTrigger Price of 3.01 on Tuesday, May 1st 2012. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=mnov&id=270016

From August 2009 to April 2012, an aggregate amount of 3315650 shares of MNOV have been shorted for a total dollar value of $9946950. The MNOV SqueezeTrigger price of $3.01 is the volume weighted average price that all shorts are short in shares of MNOV. There is still approximately $259,065 of potential short covering in shares of MNOV.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger Price for each stock that has been shorted. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of short squeeze events. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com .

MEDICINOVA INC (NASDAQ:MNOV) - MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs principally in the United States. The companys development pipeline includes programs that are in clinical development for the treatment of asthma, acute exacerbations of asthma, multiple sclerosis, central nervous system disorders, interstitial cystitis, solid tumor cancers, generalized anxiety disorder/insomnia, preterm labor, and urinary incontinence. Its principal product development programs consist of MN-221, which completed Phase II clinical trial for the treatment of acute exacerbations of asthma, and completed Phase Ib clinical trial for the treatment of chronic obstructive pulmonary disease; MN-166 that has completed Phase II clinical trial for the treatment of multiple sclerosis; and AV411, which has advanced through multiple Phase I and IIa clinical trials for the treatment of central nervous system disorders. The companys other product development programs include MN-001, which completed Phase II/III clinical trial for the treatment of interstitial cystitis and an oral dosing formulation prototype for the treatment of bronchial asthma; MN-029 that completed Phase I clinical trial for the treatment of solid tumors; MN-305, which completed Phase II/III clinical trial for the treatment of generalized anxiety disorder and Phase II clinical trial for the treatment of insomnia; MN-221 that completed a Phase I clinical trial for the treatment of preterm labor; and MN-246, a Phase I clinical trial completed product for the treatment of urinary incontinence. Its preclinical development products comprise MN-447 and MN-462 for the treatment of thrombotic disorders. The company was founded in 2000 and is headquartered in San Diego, California.

The SqueezeTrigger database of approximately 1 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com

About BUYINS.NET

BUYINS.NET, http://www.buyins.net, monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. [symbol] has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net